Marlyn Mayo

11PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersToxicology (incl. clinical toxicology)ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 02, 2026
Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.

Anish Reddy, Adrielly Martins, Christopher L Bowlus

|Jun 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

Cynthia Levy, Palak J Trivedi, Kris V Kowdley

|Mar 20, 2024
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

David E J Jones, Ulrich Beuers, Alan Bonder

|Dec 28, 2023
Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply.

Marlyn J Mayo, John M Vierling, Christopher L Bowlus

|Dec 20, 2023
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.

Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield

|Oct 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Marlyn J Mayo, John M Vierling, Christopher L Bowlus

Pageof 2